InterMune Inc. stopped a Phase III trial of Actimmune (interferon gamma-1b) in ovarian cancer due to ineffectiveness and will not plan any further oncology studies of the product going forward, as it falls outside the company's core focus. (BioWorld Today)

InterMune Inc. stopped a Phase III trial of Actimmune (interferon gamma-1b) in ovarian cancer due to ineffectiveness and will not plan any further oncology studies of the product going forward, as it falls outside the company's core focus. (BioWorld Today)

At last, the FDA cleared Ranexa (ranolazine extended-release tablets), the first new angina drug approved in the U.S. in more than 20 years. (BioWorld Today)

At last, the FDA cleared Ranexa (ranolazine extended-release tablets), the first new angina drug approved in the U.S. in more than 20 years. (BioWorld Today)